Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $69.40 ($1.1M) on 2026-06-01, disclosed to the SEC on 2026-06-03.
Scheduled sale ($1.1M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $69.40 | 3,557 | $247K | 23.4% |
| 2 | $70.50 | 8,149 | $575K | 54.4% |
| 3 | $71.38 | 3,294 | $235K | 22.3% |
| Total | $70.43 avg | 15,000 | $1.1M | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-05-01 | $1.1M | — | Filing → |